TRICYCLIC ANTIDEPRESSANT PLASMA-LEVELS AFTER AUGMENTATION WITH CITALOPRAM - A CASE-STUDY

被引:32
作者
BAETTIG, D
BONDOLFI, G
MONTALDI, S
AMEY, M
BAUMANN, P
机构
[1] UNIV PRILLY LAUSANNE,DEPT PSYCHIAT ADULTE,UNITE BIOCHIM,PRILLY,SWITZERLAND
[2] UNIV PRILLY LAUSANNE,DEPT PSYCHIAT ADULTE,PSYCHOPHARMACOL CLIN,PRILLY,SWITZERLAND
关键词
CITALOPRAM; DEPRESSION; TRICYCLIC ANTIDEPRESSANTS; PHARMACOKINETIC INTERACTION; PLASMA LEVEL; CASE REPORT; DRUG INTERACTION;
D O I
10.1007/BF00316483
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
In a depressed patient, the addition of citalopram 40-60 mg per day to treatment with amitriptyline 75 mg per day had no effect on the plasma levels of amitriptyline and nortriptyline, but it led to clinical improvement without the appearance of adverse effects. This and similar findings in four other patients comedicated with citalopram and amitriptyline (2 patients), clomipramine or maprotiline suggest that citalopram differs from other selective serotonin reuptake inhibitors, such as fluvoxamine and fluoxetine, which have been shown to increase tricyclic antidepressant plasma levels.
引用
收藏
页码:403 / 405
页数:3
相关论文
共 16 条
[1]  
ARANOW RB, 1989, AM J PSYCHIAT, V146, P911
[2]   AMITRIPTYLINE PHARMACOKINETICS AND CLINICAL-RESPONSE .2. METABOLIC POLYMORPHISM ASSESSED BY HYDROXYLATION OF DEBRISOQUINE AND MEPHENYTOIN [J].
BAUMANN, P ;
JONZIERPEREY, M ;
KOEB, L ;
KUPFER, A ;
TINGUELY, D ;
SCHOPF, J .
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 1986, 1 (02) :102-112
[3]   FLUOXETINE INDUCES ELEVATION OF DESIPRAMINE LEVEL AND EXACERBATION OF GERIATRIC NONPSYCHOTIC DEPRESSION [J].
BELL, IR ;
COLE, JO .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 1988, 8 (06) :447-448
[4]   FLUVOXAMINE-TRICYCLIC ANTIDEPRESSANT INTERACTION - AN ACCIDENTAL FINDING [J].
BERTSCHY, G ;
VANDEL, S ;
VANDEL, B ;
ALLERS, G ;
VOLMAT, R .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1991, 40 (01) :119-120
[5]   FLUOXETINE AND NORFLUOXETINE ARE POTENT INHIBITORS OF P450IID6 - THE SOURCE OF THE SPARTEINE DEBRISOQUINE OXIDATION POLYMORPHISM [J].
BROSEN, K ;
SKJELBO, E .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1991, 32 (01) :136-137
[6]   CLINICAL-SIGNIFICANCE OF THE SPARTEINE-DEBRISOQUINE OXIDATION POLYMORPHISM [J].
BROSEN, K ;
GRAM, LF .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1989, 36 (06) :537-547
[7]  
CREWE HK, 1991, BR J CLIN PHARM, V32
[8]  
DOWNS JM, 1989, J CLIN PSYCHIAT, V50, P226
[9]   SERUM FLUOXETINE AND NORFLUOXETINE CONCENTRATIONS AND ANTIDEPRESSANT RESPONSE [J].
KELLY, MW ;
PERRY, PJ ;
HOLSTAD, SG ;
GARVEY, MJ .
THERAPEUTIC DRUG MONITORING, 1989, 11 (02) :165-170
[10]   CITALOPRAM - A REVIEW OF ITS PHARMACODYNAMIC AND PHARMACOKINETIC PROPERTIES, AND THERAPEUTIC POTENTIAL IN DEPRESSIVE-ILLNESS [J].
MILNE, RJ ;
GOA, KL .
DRUGS, 1991, 41 (03) :450-477